4.7 Meeting Abstract

Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 35, Issue 18, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2017.35.18_suppl.LBA5003

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available